Adaptimmune Therapeutics Plc (ADAP) — Cash Flow Reinvestment Rate

Latest as of June 2024: 0.03x

Adaptimmune Therapeutics Plc (ADAP) has a Cash Flow Reinvestment Rate of 0.03x as of June 2024, reinvesting $1.50 Million (capex $754.55K plus investments $-743.00K) from operating cash flow of $47.39 Million. Explore ADAP capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.03x
(Capex + Investments) / Operating CF

Total Reinvested

$1.50 Million
Capex + Investments

Operating Cash Flow

$47.39 Million
USD

Capital Expenditures

$754.55K
USD

Adaptimmune Therapeutics Plc Cash Flow Reinvestment Rate (2013–2021)

Historical reinvestment intensity for Adaptimmune Therapeutics Plc across 2 annual periods. Also explore Adaptimmune Therapeutics Plc asset portfolio for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Adaptimmune Therapeutics Plc (2013–2021)

Year-by-year capital reinvestment analysis for Adaptimmune Therapeutics Plc. For live market cap and broader valuation context, see market value of Adaptimmune Therapeutics Plc.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2021 8.70x $93.36 Million $10.73 Million $8.78 Million ▲ +485.6%
2013 1.49x $55.33 Million $37.23 Million $1.45 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow